The first clinical trial participant of the new drug Leqembi, Dan Harrington, reports on the positive changes the drug has had on his condition. If the European Medicines Agency gives the green light, it is possible that the active ingredient will also be available in Germany sometime in the second half of 2024 or early 2025.
Alzheimer’s patient tests new drug: This is how it changes his life
